Citadel Advisors
ORMP icon

Citadel Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Citadel Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Sell
41,565
-57,064
-58% -$227K ﹤0.01% 12070
2026
Q1 		$335K Sell
98,629
-97,391
-50% -$330K ﹤0.01% 10221
2025
Q4 		$559K Buy
196,020
+84,313
+75% +$217K ﹤0.01% 8761
2025
Q3 		$295K Buy
111,707
+24,391
+28% +$53.9K ﹤0.01% 10406
2025
Q2 		$196K Buy
87,316
+87,283
+264,494% +$193K ﹤0.01% 10696
2025
Q1 		$71 Sell
33
-72,456
-100% -$167K ﹤0.01% 14340
2024
Q4 		$175K Buy
72,489
+51,087
+239% +$121K ﹤0.01% 10653
2024
Q3 		$52.2K Buy
+21,402
New +$52.2K ﹤0.01% 11859
2024
Q1 		– Sell
-31,347
Closed -$87.7K – 15243
2023
Q4 		$72.4K Buy
+31,347
New +$67K ﹤0.01% 11347
2023
Q2 		– Sell
-54,162
Closed -$174K – 14979
2023
Q1 		$118K Sell
54,162
-1,979
-4% -$6.29K ﹤0.01% 11023
2022
Q4 		$675K Sell
56,141
-50,725
-47% -$394K ﹤0.01% 7619
2022
Q3 		$692K Sell
106,866
-541,967
-84% -$4.39M ﹤0.01% 7765
2022
Q2 		$2.97M Buy
648,833
+463,354
+250% +$2.48M ﹤0.01% 4773
2022
Q1 		$1.6M Sell
185,479
-348,746
-65% -$3.57M ﹤0.01% 6580
2021
Q4 		$7.63M Buy
534,225
+515,329
+2,727% +$10.8M ﹤0.01% 3542
2021
Q3 		$416K Sell
18,896
-17,498
-48% -$298K ﹤0.01% 10325
2021
Q2 		$487K Buy
36,394
+16,959
+87% +$194K ﹤0.01% 10116
2021
Q1 		$198K Buy
+19,435
New +$160K ﹤0.01% 11716
2020
Q4 		– Sell
-32,537
Closed -$106K – 11356
2020
Q3 		$85K Buy
+32,537
New +$113K ﹤0.01% 9361
2015
Q4 		– Sell
-5,236
Closed -$29K – 9054
2015
Q3 		$29K Buy
5,236
+5,139
+5,298% +$32.3K ﹤0.01% 7941
2015
Q2 		$1K Buy
+97
New +$664 ﹤0.01% 8645
2015
Q1 		– Sell
-6,921
Closed -$32K – 8755
2014
Q4 		$32K Buy
+6,921
New +$45.5K ﹤0.01% 7507

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors's ORMP Position: Q2 2026 in Review

Citadel Advisors reduced its Oramed Pharmaceuticals (ORMP) stake by 58% in Q2 2026, selling an estimated $227K and leaving 41,565 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #12070.

Citadel Advisors first reported a position in ORMP in Q4 2014 and has held it in 22 quarters since. The position peaked at $7.63M in Q4 2021. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Citadel Advisors held 41,565 shares of Oramed Pharmaceuticals worth $200K as of Q2 2026.
  • Citadel Advisors sold 57,064 Oramed Pharmaceuticals shares in Q2 2026, an estimated $227K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12070 holding.
  • Citadel Advisors first reported a position in Oramed Pharmaceuticals in Q4 2014 and has held it in 22 quarters since.
  • Citadel Advisors's Oramed Pharmaceuticals position peaked at $7.63M in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.